RE: RE: Endo - New Deal - PR
Endo has about 100 million shares outstanding. They are paying 2.9 billion$$ to add to their net profit 0.60$ in 2012 - or about 60 million$$ - a ratio of about 48 times future profits ( projected 0.80 for 2013 or a ratio of about 35 times) . This ratio is close to the one we saw in their last large acquisition.
Conclusion :
- they are ready to pay a lot for something they know "trouble free"
- they probably dont intend to buy BNC before being ABSOLUTELY sure that they will get FDA approval